- Open Access
Krill oil reduces plasma triacylglycerol level and improves related lipoprotein particle concentration, fatty acid composition and redox status in healthy young adults - a pilot study
© Berge et al. 2015
- Received: 4 November 2015
- Accepted: 28 November 2015
- Published: 15 December 2015
Lipid abnormalities, enhanced inflammation and oxidative stress seem to represent a vicious circle in atherogenesis, and therapeutic options directed against these processes seems like a reasonable approach in the management of atherosclerotic disorders. Krill oil (RIMFROST Sublime®) is a phospholipid-rich oil with eicosapentaenoic acid (EPA): docosahexaenoic acid (DHA) ratio of 1.8:1. In this pilot study we determined if krill oil could favourable affect plasma lipid parameters and parameters involved in the initiation and progression of atherosclerosis.
The study was conducted as a 28 days intervention study examining effect-parameters of dietary supplementation with krill oil (832.5 mg EPA and DHA per day). 17 healthy volunteers in the age group 18–36 (mean age 23 ± 4 years) participated. Plasma lipids, lipoprotein particle sizes, fatty acid composition in plasma and red blood cells (RBCs), plasma cytokines, antioxidant capacity, acylcarntines, carnitine, choline, betaine, and trimethylamine-N-oxide (TMAO) were measured before and after supplementation.
Plasma triacylglycerol (TAG) and large very-low density lipoprotein (VLDL) & chylomicron particle concentrations decreased after 28 days of krill oil intake. A significant reduction in the TAG/HDL cholesterol resulted. Krill oil supplementation decreased n-6/n-3 polyunsaturated fatty acids (PUFA) ratio both in plasma and RBCs. This was due to increased EPA, DHA and docosapentaenoic acid (DPA) and reduced amount of arachidonic acid (AA). The increase of n-3 fatty acids and wt % of EPA and DHA in RBC was of smaller magnitude than found in plasma. Krill oil intake increased the antioxidant capacity, double bond index (DBI) and the fatty acid anti-inflammatory index. The plasma atherogenicity index remained constant whereas the thrombogenicity index decreased. Plasma choline, betaine and the carnitine precursor, γ-butyrobetaine were increased after krill oil supplementation whereas the TMAO and carnitine concentrations remained unchanged.
Krill oil consumption is considered health beneficial as it decreases cardiovascular disease risk parameters through effects on plasma TAGs, lipoprotein particles, fatty acid profile, redox status and possible inflammation. Noteworthy, no adverse effects on plasma levels of TMAO and carnitine were found.
- Krill oil
- Lipoprotein particle size
Cardiovascular disease (CVD) is the leading cause of death worldwide . Plasma lipids, especially cholesterol and triacylglycerol (TAG), are associated with risk for CVD and coronary artery disease [2–4]. Cholesterol is mostly transported in plasma by specific cholesterol-rich lipoproteins as low-density lipoproteins (LDL) or high-density lipoproteins (HDL). TAG is carried in very low-density lipoproteins (VLDL) and chylomicrons (CMs) Human trials have shown that plasma concentrations of high LDL-cholesterol, low HDL-cholesterol and high TAG are associated with elevated CVD risk [5, 6]. Recently, it has been found that TAG-rich lipoproteins causally influence risk for coronary artery disease (CAD) . Moreover, small dense LDL particles are shown to be more atherogenic than the larger and less dense LDL particles . Much research has been performed to the study of various interventions for the prevention of CVD. Since 1970, regular consumption of fatty fish or fish oils has been stated to have several positive effects on CVD because of the presence of n-3 fatty acids, namely EPA (C20:5n-3) and DHA (C22:6n-3), and lately docosapentanenoic acid (DPA, C22:5n-3) has also become a focus of interest [9, 10]. Indeed, EPA and DHA supplementations have been shown to consistently lower plasma TAG concentration [11, 12] although the efficacy of EPA and DHA in the prevention of CVD has been challenged in the recent meta-analyses [13–15]. Thus, clinical cardiovascular benefits of these n-3 fatty acids have been reported in several, but not all human trials. Most probably EPA and/or DHA do not affect CVD through a single factor, but rather due to several factors such as plasma lipid concentration [11, 12], systemic and local inflammation , vascular endothelial function [17, 18], and oxidative stress [17, 18].
Krill oil from Antarctic krill (Euphausia superba) has in the last years emerged on the market as an alternative source of EPA and DHA. An increasing number of studies with krill oil demonstrate health benefits in animals as well as in humans [19–22]. While fish oils have their bioactive n-3 fatty acids incorporated into TAG or ethylesters, krill oil has EPA and DHA esterified in phospholipids (PLs) in particular phosphatidylcholine (PC). Furthermore, the polar structure of PLs was shown to increase the bioavailability of EPA and DHA from krill oil in comparison to fish oil . In addition to its high content of PLs, krill oil contains the antioxidant astaxanthin, which might enhance stability of n-3 fatty acids and preserve them from lipid oxidation.
Trimethylamine-N-oxide (TMAO) is a diet and microbiota-dependent proatherogenic metabolite and a proposed cardiovascular risk marker [24–26]. It´s precursors are betaine, choline and carnitine [24, 27], thus a high intake of PC and choline could potentially influence plasma levels of TMAO.
The main objective of this pilot study was to investigate the effect of krill oil on plasma lipids, lipoprotein particle concentrations and fatty acid profile in plasma and red blood cells (RBC). In addition, the effect of krill oil on inflammation, antioxidant capacity (AOC), and changes in plasma levels of TMAO was evaluated.
Baseline characteristics of the study participants
The study included 18 healthy volunteers, of which all completed the supplementation period. One volunteer had a major protocol deviation, and was excluded. Thus, 17 healthy individuals (15 females, 2 males) were included in the final analysis. The mean age was 23 years (range 20–33) and the BMI 20.9 kg/m2 (range 17.6-25.5) (data not shown). Compliance of the intervention was >95 % for all subjects during the period (mean 100 %; range 96 % to 100 %).
Effect of krill oil supplementation on safety parameters
1.5 ± 2.1
2.0 ± 4.3
19.4 ± 6.4
20.0 ± 8.4
25.6 ± 5.4
26.6 ± 6.7
61.7 ± 18.6
61.8 ± 16.0
6.9 ± 1.9
8.4 ± 4.9
71.5 ± 4.7
71.1 ± 4.2
46.9 ± 2.4
46.6 ± 2.3
12.9 ± 4.7
14.0 ± 5.2
6.3 ± 2.5
6.6 ± 3.7
4.7 ± 0.4
4.8 ± 0.4
Effect on plasma lipids and lipoprotein particle size
Effect of krill oil supplementation on plasma lipoprotein concentrations
VLDL particle concentration, nmol/L
End of study
Total VLDL & Chylomicron
32.8 ± 22.4
28.1 ± 18.8
Large VLDL & Chylomicron
1.3 ± 1.0
1.0 ± 0.6
11.1 ± 10.4
8.9 ± 8.7
20.4 ± 12.9
18.3 ± 14.0
LDL particle concentration, nmol/L
873.6 ± 288.9
943.4 ± 352.8
447.8 ± 201.5
528.5 ± 218.4
352.1 ± 230.0
348.5 ± 260.8
73.7 ± 43.2
66.4 ± 76.4
HDL particle concentration, μmol/L
32.1 ± 5.6
33.4 ± 5.7
8.7 ± 2.8
9.8 ± 3.6
10.4 ± 5.6
10.1 ± 5.7
13.0 ± 3.5
13.5 ± 4.3
Fatty acid composition in plasma and RBC
Effect of krill oil on plasma and red blood cell (RBC) fatty acid profile
Fatty acids Wt %
End of study
End of study
31.8 ± 0.7
31.6 ± 1.0
40.9 ± 0.6
40.7 ± 0.6
25.2 ± 2.3
23.6 ± 2.9
17.5 ± 0.7
17.3 ± 0.9
42.8 ± 2.7
44.6 ± 3.2
41.4 ± 0.7
41.8 ± 0.8
37.0 ± 2.7
35.1 ± 3.7
29.9 ± 1.8
28.5 ± 1.7
27.7 ± 2.7
26.8 ± 3.5
9.1 ± 1.0
8.7 ± 1.0
1.5 ± 0.3
1.3 ± 0.3
1.5 ± 0.4
1.4 ± 0.3
7.0 ± 1.6
6.3 ± 1.4
15.9 ± 1.5
15.1 ± 1.4
0.1 ± 0.03
0.1 ± 0.02
0.4 ± 0.1
0.4 ± 0.07
5.7 ± 1.5
9.4 ± 1.6
11.3 ± 1.7
13.2 ± 1.5
0.7 ± 0.2
0.7 ± 0.3
0.2 ± 0.03
0.2 ± 0.04
1.1 ± 0.6
3.6 ± 0.8
1.2 ± 0.4
2.5 ± 0.4
0.6 ± 0.1
0.8 ± 0.2
2.8 ± 0.4
3.1 ± 0.3
3.2 ± 0.8
3.9 ± 0.7
7.0 ± 1.2
7.4 ± 1.0
Effect on antioxidant status
Effect on systemic inflammation
Krill oil supplementation in humans could be expected to have anti-inflammatory potential in plasma as the fatty acid anti-inflammatory index increased (Fig. 2g). However, the plasma cytokines IL-1β, IL-10, IL-17, granulocyte colony-stimulating factor (G- CSF) and tumor necrosis factor alpha (TNFα) were unchanged after krill oil intake (data not shown).
Effect on choline, betaine, carnitine and TMAO
Effect on plasma acylcarnitine level
The present study has shown that 28 days supplementation of krill oil had significant biological effects in healthy subjects. Moreover, intake of this EPA-and DHA rich PC-oil beneficially affected several parameters linked to CVD-risk, including plasma lipids, lipoprotein particle concentrations, fatty acid composition, redox status and potentially inflammation and thrombogenicity. However, a small increase in cholesterol was observed. The krill oil intake did not change the safety parameters (Table 1).
Krill oil intake reduced plasma TAG levels due to decreased concentration of large VLDL & CM particles (Table 2), concomitant with increased concentration of large HDL particles and decreased TAG/HDL ratio (Fig. 1i). Large LDL particles also increased after 28 days krill oil supplementation and this resulted in a modest, but significantly higher plasma total cholesterol level (Fig.1d). However, total cholesterol/HDL, a robust risk parameter in European populations , was unaltered (Fig. 1j). The increase in large HDL particles in response to n-3 PUFA supplementation has been demonstrated in several studies [35, 36], and may be explained by a reduced exposure to cholesterol ester transfer protein (CETP)-mediated transfer of cholesterol from HDL particles due to a lower concentration of TAG rich large VLDL and CM. Interestingly, the increased concentration of large HDL-and LDL particles has mainly been found with DHA, but not EPA supplementation [37, 38]. Noteworthy, the concentration of the more atherogenic small LDL particles remained constant after krill oil supplementation.
It has been assumed that EPA or DHA, or both, are responsible for the TAG-lowering effect after supplementation of n-3 PUFA. Most studies have used fish oil with various contents of EPA and DHA, and only a few studies have examined the effect of EPA and DHA separately to determine for the effects for each fatty acid. Previous studies have demonstrated n-3 PUFA supplementation to lower plasma TAG levels when ingesting 2–4 g EPA and DHA per day for 6 weeks or longer, although the effect seem to be strongest among people with an unfavourable risk profile [11, 12, 39]. Supplementation with 4 g EPA per day for 6–7 weeks has been shown to reduce TAG by 21 %  and 23 %  in mildly hyperlipidaemic subjects, and by 12 % in healthy subjects . The present study showed a reduction in TAG levels (12 %, p = 0.02) in healthy young adults after 28 days of supplementation with 832.5 mg EPA and DHA from krill oil with an EPA:DHA ratio of approximately 1.8:1. This indicates a high bioavailability of krill oil (RIMFROST Sublime®) and a subsequent rapid effect on lipid metabolism. Moreover, this is in line with a recent study in adults with high TAG levels where a dose of 0.5-2 g/day krill oil significantly reduced plasma TAG .
Composition of the krill oil (wt %)
Krill oil capsules
C18:1 (n-9) + (n-7) + (n-5)
C20:1 (n-9) + (n-7)
C22:1 (n-11) + (n-9) + (n-7)
Total polar lipids
Free fatty acids
Total neutral lipids
Free fatty acids
Studies in cultured rat hepatocytes have shown that EPA increases mitochondrial fatty acid oxidation , and as recently reviewed, plasma acylcarnitine levels can give an indication on mitochondrial function . When acyl-CoAs accumulate in the mitochondrial matrix, acylcarnitine formation is favoured, which can exit the mitochondrion and access the peripheral circulation. The intra-mitochondrial relationship between acyl-CoA and free CoA is reflected by the extra-mitochondrial acylcarnitine to free carnitine ratio, given that any mitochondrial acyl-CoA accumulation leads to a corresponding increase in acylcarnitines. In situations of inefficient β-oxidation, intermediates such as octanoyl- and palmitoylcarnitine will be formed, which are considered toxic . Elevated palmitoylcarnitine has been associated with poor prognosis in chronic heart failure (CHF) patients . In the present study the plasma level of octanoylcarnitine was decreased by krill oil supplementation. Altogether, this suggests that the krill oil intervention may be responsible for more efficient fatty acid oxidation of medium-chain length fatty acids. Noteworthy, this is in consistence with findings in animal studies where krill oil was shown to influence metabolic pathways, including fatty acid oxidation, lipid biosynthesis and acylcarntine turnover [48, 49].
Choline is mainly utilized for PC biosynthesis, which is required for membrane formation and can take place through two pathways, namely CDP-choline (Kennedy) pathway and the phospatidylethanolamine N-methyltransferase (PEMT) pathway. Moreover, choline can be oxidized to betaine, which is involved in the remethylation of homocysteine to methionine in the one-carbon cycle . In the present study plasma choline and betaine was increased by krill supplementation, indicating an increased PC degradation and increased choline oxidation, respectively. Choline is an important nutrient and is predominantly obtained from the diet [51, 52], although it can be synthesised de novo. In a recent European study, the average choline intake was below the adequate intake (set by the Institute of Medicine in the USA) in most of the population groups considered . Thus, krill oil can be a well-suited supplement for populations vulnerable to choline deficiency.
TMAO is formed in the liver from trimethylamine, a product generated by the gut microbiota from dietary PC, choline and carnitine. Trimethylamine can also be generated from betaine . Recent studies have shown that TMAO is a diet and microbiota-dependent proatherogenic metabolite and cardiovascular risk marker [24–27]. Interestingly, in the present study the plasma TMAO level remained constant by krill oil supplementation, demonstrating that the extra choline intake did not influence TMAO generation.
AA is a precursor for prostaglandins  and is considered proinflammatory. Krill oil supplementation decreased the level of AA and increased amounts of n-3 PUFAs in plasma and RBC resulting in an increased anti-inflammatory fatty acid index. This implies that krill oil intake has anti-inflammatory properties. The plasma cytokines, however, remained unchanged. The plasma total antioxidant status significantly increased after krill oil supplementation (Fig. 3a) and it was of interest that AOC positively correlated with the plasma and RBC levels of EPA and wt % of EPA and DHA. Moreover, plasma AOC correlated with RBC DBI but no correlation was found between AOC and DHA concentrations in plasma and RBC after krill oil intake (data not shown). Whether the presence of astaxanthin is responsible for the oxidative protective effect observed, should be considered . This is an important point, as the removal of protective trace compounds in the generation of highly purified PUFAs has been reported to reduce the beneficial effect of fish oil supplements .
28 days of krill oil supplementation in healthy young adults reduced plasma TAG and large VLDL & CM particle concentration, whereas the concentrations of large HDL and LDL were increased. The changes in fatty acid composition in plasma and RBC were accompanied by increased n-3 PUFAs, decreased level of AA and increased the plasma antioxidant status. Furthermore, no adverse effects of krill oil intake on plasma TMAO levels were found. Thus, a dose of 832.5 mg EPA and DHA from krill oil had beneficial biological effects in persons with a normal lipid profile, and may prevent the development of several risk factors related to CVD.
18 subjects in the age group 18–36, with a body mass index (BMI; in kg/m2) of 17–29.9 and in a generally good health, were recruited to the pilot study. Exclusion criteria were disease related to fat metabolism or digestion, acute or chronic inflammatory conditions, liver dysfunctions, pregnancy (all self-reported), obesity (defined as a BMI ≥30), inability to swallow capsules and unwillingness to take blood samples.
The intervention used was krill oil capsules (RIMFROST Sublime ®, Rimfrost AS, Fosnavaag, Norway). The lipid- and fatty acid composition of the oil is presented in Table 4. Each capsule (500 mg) contained 210 mg PLs and 120 mg n-3 PUFA, of which 60 mg was EPA and 32.5 mg DHA. The participants received 9 capsules per day for 28 days, corresponding to a daily dose of 832.5 mg EPA and DHA Moreover, the oil contained 192 mg astaxanthin per kg.
Subjects were recruited through advertisements presented at the University of Bergen and the Bergen University College (Norway). After written informed consent to participate was provided, blood samples were drawn, and body weight and height were recorded to calculate body mass index (BMI; kg/m2). Study participants were interviewed about their dietary intake of food stuffs rich in n-3 fatty acids and PLs, focusing on the amount and frequency of the last month intake. Participants were advised to maintain a steady intake of these food items during the study period, refrain from the use of all nutritional supplements, and to maintain their body weight. At the end of the study, all participants were asked to answer questionnaires to assess self-reported compliance and product tolerance. The 18 subjects included all completed the intervention period. However, one subject (male) was excluded from the final analysis due to protocol deviation revealed by the questionnaires.
Blood sample collection
Blood samples were collected from subjects fasted overnight and seated for 15 minutes, at the beginning (baseline) and end of the study. At both time points, blood samples were centrifuged and EDTA-plasma and serum was collected after a minimum of 15 minutes and maximum of 30 minutes at room temperature. Blood samples for isolation of RBC was drawn in EDTA-tubes, centrifuged at 3000 rpm for 10 minutes, and plasma and interface removed. RBC was then washed three times in phosphate buffered saline (PBS), with subsequent centrifugation and removal of the buffy coat (white blood cells) between each wash. Finally, the original volume was reconstituted using PBS. All samples were aliquoted and stored at −80°C for further analysis.
Total fatty acid composition in the red blood cells (RBC) and in plasma
The total fatty acid composition was analysed in RBC and in EDTA-plasma, as previously described .
The omega-3 index is defined as the sum of EPA and DHA in RBC, expressed as a percentage of the total fatty acid (TFA) content. The anti-inflammatory index is defined as the sum of EPA (C20:5n-3), dihomo-gamma-linolenic acid (DGLA, C20:3n-6), DHA (C22:6n-3) and DPA (C22:5n-3), divided on AA (C20:4n-6), multiplied with 100. The double bound index (DBI) is defined as (MUFA + 2*(C18:2n6 + C20:2n6 + C22:2n6) + 3*(C18:3n6 + C18:3n3 + C20:3n9 + C20:3n6) + 4*(C18:4n3 + C20:4n6 + C20:4n3 + C22:4n6) + 5*(C20:5n3 + C21:5n3 + C22:5n6 + C22:5n3) + 6*(C22:6n3))/TFA. The atherogenicity index (AI) and the thrombogenenicity (TI) were determined according to Ulbricht and Southgate  equations: AI = (C12:0 + 4*C14:0 + C16:0)/(ΣMUFA + Σ(n-6 PUFA) + Σ(n-3 PUFA)). TI = (C14:0 + C16:0 + C18:0)/(0.5*ΣMUFA + 0.5*Σ(n-6 PUFA) + 3*Σ(n-3 PUFA) + (Σ(n-3 PUFA)/Σ(n-6 PUFA)), where ΣMUFA, Σ(n-6 PUFA), and Σ(n-3 PUFA) are the sum of MUFA, n-6 and n-3 PUFA in wt % of total fatty acids, respectively.
Lipids and lipoproteins
Lipids were measured enzymatically in EDTA-plasma on a Hitachi 917 system (Roche Diagnostics GmbH, Mannheim, Germany) using the triacylglycerol (GPO-PAP), cholesterol (CHOD-PAP), HDL-cholesterol plus and LDL-cholesterol plus kit from Roche Diagnostics, the non-esterified fatty acid (NEFA FS) kit and the Phospholipids FS kit 17 from DiaSys Diagnostic Systems GmbH (Holzheim, Germany).
Lipoprotein size was measured in EDTA-plasma with nuclear magnetic resonance (NMR) spectroscopy by LabCorp Inc (Burlington, NC, USA), using the NMR LipoProfile® test (http://www.labcorp.com).
Plasma choline, betaine, trimethyllysine (TML), butyrobetaine and trimethylamine N-oxide (TMAO), as well as L-carnitine, acetylcarnitine, proponylcarnitine, octanoylcarnitine, iso-/L-valerylcarnitine and palmitoylcarnitine, were analysed in EDTA-plasma using LC/MS/MS as previously described [58, 59].
Clinical laboratory measurements, including safety parameters were measured in EDTA-plasma using routine methods at the central laboratory at Haukeland University Hospital (Bergen, Norway).
Total AOC of plasma was measured using the total antioxidant capacity kit (Abcam, Cambridge, UK) according to the manufacturer’s instructions. The protein mask was not used, enabling the analysis of both small molecule antioxidants and proteins ability to reduce Cu2+ to Cu+. In brief, EDTA-plasma was allowed to reduce Cu2+ for 1.5 hour at room temperature on an orbital shaker. The absorbance was measured at 570 nm using a plate reader. Results were expressed as trolox equivalents according to a trolox standard curve.
The levels of IL-1β, IL-10, IL-17, G-CSF and TNF-α were measured in plasma samples using a custom-made multiplex MILLIPLEX MAP kit (Millipore Corp., St. Charles, IL, USA), and the assay solution was read by the Bio-Plex array reader (Bio-Rad, Hercules, CA, USA) and determined with the Bio-Plex Manager Software 4.1.
All participants were asked to answer a questionnaire to assess compliance, supplementation regime, product tolerance and to report of possible gastrointestinal (GI) symptoms occurring when ingesting the supplement. Compliance was further determined by capsule logs and validated by count of capsules in surplus. An authorised clinical nutritionist interviewed the participants into the regime, and general product tolerance.
All examinations and blood samples were performed at the Department of Clinical Science, University of Bergen, Norway. The study protocol was approved by the Regional Ethics Committee of Northern Norway (Registration number 2013/2152), and registered on ClinicalTrials.gov (NCT02053415). All procedures were carried out in accordance with the ethical standards of the Helsinki declaration of 1975, revised in 2004, for experiments involving humans (http://www.wma.net/en/30publications/10policies/b3/index.html).
Data sets were analysed using Prism Software (Prism Graph-Pad Software, version 6, San Diego, California, USA) to determine statistical significance. The results are reported as means per group with their standard deviations (SD), with exception of age, BMI and compliance, which is reported as mean with range. Wilcoxon signed-rank test was performed to evaluate statistical differences of matched pairs. Correlation coefficients (R) were determined by Spearman correlation, and linear regressions are shown in selected figures. P-values < 0.05 were considered significant.
The authors would like to thank Kari Williams, Elin Strand, Liv Kristine Øysæd, Kari Mortensen, Torunn Eide and Randi Sandvik for valuable technical assistance. We also thank all the study participants and the bachelor student Cecilie Larsen in Human Nutrition (University of Bergen). The study was financed by Rimfrost AS and the Bergen Research Foundation.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- The top 10 causes of death - Fact sheet. http://www.who.int/mediacentre/factsheets/fs310/en. Accessed 4 Dec 2015]
- World Health Organization (WHO). Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk. 2007.Google Scholar
- Emberson JR, Whincup PH, Morris RW, Walker M. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J. 2003;24:1719–26.View ArticlePubMedGoogle Scholar
- Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effects of potentially modifiable risk factors associated with myocardial infarction in the 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–52.View ArticlePubMedGoogle Scholar
- Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.View ArticlePubMedGoogle Scholar
- Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–30.View ArticlePubMedGoogle Scholar
- Egeland GM, Igland J, Sulo G, Nygard O, Ebbing M, Tell GS. Non-fasting triglycerides predict incident acute myocardial infarction among those with favourable HDL-cholesterol: Cohort Norway. Eur J Prev Cardiol. 2015;22:872–81.View ArticlePubMedGoogle Scholar
- Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res. 1998;39:1263–73.PubMedGoogle Scholar
- Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112:298–304.View ArticlePubMedGoogle Scholar
- Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr. 2012;107 Suppl 2:S201–213.View ArticlePubMedGoogle Scholar
- Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care. 2006;9:95–104.View ArticlePubMedGoogle Scholar
- von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc Health Risk Manag. 2006;2:251–62.View ArticleGoogle Scholar
- Enns JE, Yeganeh A, Zarychanski R, Abou-Setta AM, Friesen C, Zahradka P, et al. The impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2014;14:70.PubMed CentralView ArticlePubMedGoogle Scholar
- Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B. Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5:808–18.View ArticlePubMedGoogle Scholar
- Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. Jama. 2012;308:1024–33.View ArticlePubMedGoogle Scholar
- Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83:1505S–19S.PubMedGoogle Scholar
- Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004;6:461–7.View ArticlePubMedGoogle Scholar
- Massaro M, Scoditti E, Carluccio MA, De Caterina R. Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot Essent Fatty Acids. 2008;79:109–15.View ArticlePubMedGoogle Scholar
- Berge K, Musa-Veloso K, Harwood M, Hoem N, Burri L. Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels. Nutr Res. 2014;34:126–33.View ArticlePubMedGoogle Scholar
- Burri L, Johnsen L. Krill products: an overview of animal studies. Nutrients. 2015;7:3300–21.PubMed CentralView ArticlePubMedGoogle Scholar
- Ulven SM, Kirkhus B, Lamglait A, Basu S, Elind E, Haider T, et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids. 2011;46:37–46.PubMed CentralView ArticlePubMedGoogle Scholar
- Tillander V, Bjorndal B, Burri L, Bohov P, Skorve J, Berge RK, et al. Fish oil and krill oil supplementations differentially regulate lipid catabolic and synthetic pathways in mice. Nutr Metab (Lond). 2014;11:20.View ArticleGoogle Scholar
- Kohler A, Sarkkinen E, Tapola N, Niskanen T, Bruheim I. Bioavailability of fatty acids from krill oil, krill meal and fish oil in healthy subjects--a randomized, single-dose, cross-over trial. Lipids Health Dis. 2015;14:19.PubMed CentralView ArticlePubMedGoogle Scholar
- Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576–85.PubMed CentralView ArticlePubMedGoogle Scholar
- Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–84.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63.PubMed CentralView ArticlePubMedGoogle Scholar
- Rebouche CJ, Seim H. Carnitine metabolism and its regulation in microorganisms and mammals. Annu Rev Nutr. 1998;18:39–61.View ArticlePubMedGoogle Scholar
- Ikeda I, Wakamatsu K, Inayoshi A, Imaizumi K, Sugano M, Yazawa K. alpha-Linolenic, eicosapentaenoic and docosahexaenoic acids affect lipid metabolism differently in rats. J Nutr. 1994;124:1898–906.PubMedGoogle Scholar
- Willumsen N, Hexeberg S, Skorve J, Lundquist M, Berge RK. Docosahexaenoic acid shows no triglyceride-lowering effects but increases the peroxisomal fatty acid oxidation in liver of rats. J Lipid Res. 1993;34:13–22.PubMedGoogle Scholar
- Willumsen N, Skorve J, Hexeberg S, Rustan AC, Berge RK. The hypotriglyceridemic effect of eicosapentaenoic acid in rats is reflected in increased mitochondrial fatty acid oxidation followed by diminished lipogenesis. Lipids. 1993;28:683–90.View ArticlePubMedGoogle Scholar
- Assies J, Mocking RJ, Lok A, Ruhe HG, Pouwer F, Schene AH. Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr Scand. 2014;130:163–80.PubMed CentralView ArticlePubMedGoogle Scholar
- Ueland T, Svardal A, Oie E, Askevold ET, Nymoen SH, Bjorndal B, et al. Disturbed carnitine regulation in chronic heart failure--increased plasma levels of palmitoyl-carnitine are associated with poor prognosis. Int J Cardiol. 2013;167:1892–9.View ArticlePubMedGoogle Scholar
- Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet. 2012;51:553–72.View ArticlePubMedGoogle Scholar
- McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study. Lancet. 2008;372:224–33.View ArticlePubMedGoogle Scholar
- Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F, et al. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism. 2004;53:153–8.View ArticlePubMedGoogle Scholar
- Maki KC, Lawless AL, Kelley KM, Dicklin MR, Kaden VN, Schild AL, et al. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol. 2011;57:489–94.View ArticlePubMedGoogle Scholar
- Kelley DS, Siegel D, Vemuri M, Mackey BE. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr. 2007;86:324–33.PubMedGoogle Scholar
- Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, et al. Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. J Nutr. 2011;141:207–13.PubMed CentralView ArticlePubMedGoogle Scholar
- European Food Safety Authority (EFSA) Panel on Dietetic Products NaAN. Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA). In: Book Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA). 2010.Google Scholar
- Nestel P, Shige H, Pomeroy S, Cehun M, Abbey M, Raederstorff D. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr. 2002;76:326–30.PubMedGoogle Scholar
- Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. 1997;66:649–59.PubMedGoogle Scholar
- Hansen J-B, Grimsgaard S, Nilsen H, Nordøy A, Bønaa KH. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on fatty acid absorption, incorporation into serum phospholipids and postprandial triglyceridemia. Lipids. 1998;33:131–8.View ArticlePubMedGoogle Scholar
- Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res. 1997;38:2012–22.PubMedGoogle Scholar
- Ramprasath VR, Eyal I, Zchut S, Jones PJ. Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis. 2013;12:178.PubMed CentralView ArticlePubMedGoogle Scholar
- Von Schacky C, Fischer J, Weber PC. Long- term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest. 1985;76:1626–31.View ArticleGoogle Scholar
- Bjorndal B, Strand E, Gjerde J, Bohov P, Svardal A, Diehl BW, et al. Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults. Lipids Health Dis. 2014;13:82.PubMed CentralView ArticlePubMedGoogle Scholar
- Yamada KA, Kanter EM, Newatia A. Long-chain acylcarnitine induces Ca2+ efflux from the sarcoplasmic reticulum. J Cardiovasc Pharmacol. 2000;36:14–21.View ArticlePubMedGoogle Scholar
- Bjorndal B, Brattelid T, Strand E, Vigerust NF, Svingen GF, Svardal A, et al. Fish oil and the pan-PPAR agonist tetradecylthioacetic acid affect the amino acid and carnitine metabolism in rats. PLoS One. 2013;8:e66926.PubMed CentralView ArticlePubMedGoogle Scholar
- Vigerust NF, Bjorndal B, Bohov P, Brattelid T, Svardal A, Berge RK. Krill oil versus fish oil in modulation of inflammation and lipid metabolism in mice transgenic for TNF-alpha. Eur J Nutr. 2012;52:1315–25.View ArticlePubMedGoogle Scholar
- Ueland PM, Holm PI, Hustad S. Betaine: a key modulator of one-carbon metabolism and homocysteine status. Clin Chem Lab Med. 2005;43:1069–75.View ArticlePubMedGoogle Scholar
- Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Choline. In: Book Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B-6, Vitamin B12, Panthothenic Acid, Biotin, and Choline. Washington (National Acedemies Press); 1998. p. 390–422.Google Scholar
- Zeisel SH, Mar MH, Howe JC, Holden JM. Concentrations of choline-containing compounds and betaine in common foods. J Nutr. 2003;133:1302–7.PubMedGoogle Scholar
- Vennemann FB, Ioannidou S, Valsta LM, Dumas C, Ocke MC, Mensink GB, et al. Dietary intake and food sources of choline in European populations. Br J Nutrit. 2015;12:1–10Google Scholar
- Gammone MA, Riccioni G, D'Orazio N. Carotenoids: potential allies of cardiovascular health? Food Nutr Res. 2015;59:26762.View ArticlePubMedGoogle Scholar
- Clayton PR, Ladi S. From alga to omega; have we reached peak (fish) oil? J R Soc Med. 2015;108:351–7.PubMedGoogle Scholar
- Strand E, Bjorndal B, Nygard O, Burri L, Berge C, Bohov P, et al. Long-term treatment with the pan-PPAR agonist tetradecylthioacetic acid or fish oil is associated with increased cardiac content of n-3 fatty acids in rat. Lipids Health Dis. 2012;11:82.PubMed CentralView ArticlePubMedGoogle Scholar
- Ulbricht TL, Southgate DA. Coronary heart disease: seven dietary factors. Lancet. 1991;338:985–92.View ArticlePubMedGoogle Scholar
- Bjorndal B, Burri L, Wergedahl H, Svardal A, Bohov P, Berge RK. Dietary supplementation of herring roe and milt enhances hepatic fatty acid catabolism in female mice transgenic for hTNFalpha. Eur J Nutr. 2012;51:741–53.View ArticlePubMedGoogle Scholar
- Bjorndal B, Ramsvik MS, Lindquist C, Nordrehaug JE, Bruheim I, Svardal A, et al. A phospholipid-protein complex from antarctic krill reduced plasma homocysteine levels and increased plasma trimethylamine-N-oxide (TMAO) and carnitine levels in male Wistar rats. Mar Drugs. 2015;13:5706–21.PubMed CentralView ArticlePubMedGoogle Scholar